We are thrilled to announce that Aparito CEO Dr Elin Haf Davies has won the Made WITH Patients Rising Star Award for her work in developing our Patient Group Accelerator Programme. To quote Elin, “The recognition is not just for us but for every individual who has contributed to our mission of digitising what’s important to patients in a patient-centric way”.
A Collaborative Approach to Patient-Centric Solutions
At Aparito, we firmly believe in the power of co-creation. Elin developed the Patient Group Accelerator Programme to provide a unique platform where patients, caregivers, and advocacy groups can collaborate with us to create solutions that genuinely work for patients.
With Dr Elisa Ferrer and Navdeep Sahota now running the Accelerator, we work closely with patient organisations to understand and fulfill their needs by finding new endpoints relevant to their specific conditions.
By developing technological solutions, novel endpoints, and digital biomarkers designed for and with the patients, our objective is to collect sufficient exploratory data as a starting point for future validation and use in clinical trials.
Transforming the Patient Experience of Clinical Trials
Our ultimate goal is to bring equity to clinical trials, ensuring that every individual, regardless of their circumstances, has equal access to life-changing treatments.
Our Patient Group Accelerator Programme has laid the foundation for future validation and utilisation in clinical trials. These groundbreaking tools have not only allowed us to collect insightful data but have also transformed the patient experience of clinical trials and we firmly believe that this innovative approach will revolutionise the way clinical trials are conducted, making healthcare accessible to all.
Full Partnership with Patients
The novelty of our Patient Group Accelerator Programme lies in our full partnership with patients.
Working with the patients from the beginning until the end of the process, we ensure that we understand their needs and develop solutions that work for them.
The programme started in 2020 with two patient groups that help patients living with Duchenne Muscular Dystrophy (DMD) and Primary Ciliary Dyskinesia (PCD) and has since added PHA UK (Pulmonary Arterial Hypertension) and ALS Liga (amyotrophic lateral sclerosis, ALS). By collaborating with patients and advocacy groups, we can develop solutions that are tailored to meet their needs, breaking barriers, and transforming lives.
Our Patient Group Accelerator Programme is a testament to our commitment to co-creation and patient-centric solutions and we thank the patient communities who have trusted us and collaborated with us on this transformative journey.
This recognition serves as a reminder of the tremendous impact we can achieve when we come together with a shared purpose.
Let us continue to work hand in hand, breaking barriers, and transforming lives, as we strive for a future where healthcare is accessible to all.
Dr Elin Haf Davies, Aparito CEO